vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v20i5.2320vsp-2749Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEФилаггрин и атопический дерматит: клинико-патогенетические параллели и возможности терапевтической коррекцииFilaggrin and Atopic Dermatitis: Clinical and Pathogenetic Parallels and Therapeutic Possibilitieshttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Мурашкин Николай Николаевич - доктор медицинских наук, заведующий отделением дерматологии с группой лазерной хирургии Центра детской дерматологии; заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии НМИЦ здоровья детей; профессор кафедры дерматовенерологии и косметологии ЦГМА; профессор кафедры педиатрии и детской ревматологии Первого МГМУ им. И.М. Сеченова.119296, Москва, Ломоносовский пр-т, д. 2, стр. 1.Тел.: +7 (495) 967-14-20

Moscow.

m_nn2001@mail.ruhttps://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1.

Moscow.

https://orcid.org/0000-0002-8232-8936АмбарчянЭ. Т.AmbarchianEduard T.

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1.

Moscow.

https://orcid.org/0000-0002-4107-4642ЕпишевР. В.EpishevRoman V.

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1.

Moscow.

https://orcid.org/0000-0002-6034-8231МатерикинА. И.MaterikinAlexander I.

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1.

Moscow.

https://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.OpryatinLeonid A.

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1.

Moscow.

https://orcid.org/0000-0001-6884-5171СавеловаА. А.SavelovaAlena A.

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1.

Moscow.

Национальный медицинский исследовательский центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет); Центральная государственная медицинская академияРоссияNational Medical Research Center of Children's Health; Sechenov First Moscow State Medical University (Sechenov University); Central State Medical AcademyRussian FederationНациональный медицинский исследовательский центр здоровья детей; Центральная государственная медицинская академияРоссияNational Medical Research Center of Children's HealthRussian FederationНИИ педиатрии и охраны здоровья детей ЦКБ РАНРоссияResearch Institute of Pediatrics and Children's Health in “Central Clinical Hospital of the Russian Academy of Sciences”Russian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children's HealthRussian Federation202106112021205435440Copyright © Мурашкин Н.Н., Иванов Р.А., Амбарчян Э.Т., Епишев Р.В., Материкин А.И., Опрятин Л.А., Савелова А.А., 20212021Мурашкин Н.Н., Иванов Р.А., Амбарчян Э.Т., Епишев Р.В., Материкин А.И., Опрятин Л.А., Савелова А.А.Murashkin N.N., Ivanov R.A., Ambarchian E.T., Epishev R.V., Materikin A.I., Opryatin L.A., Savelova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2749

Атопический дерматит (АтД) представляет собой многофакторное воспалительное заболевание кожи, одним из элементов патогенеза которого является дисфункция эпидермального барьера. Раннее развитие АтД ассоциировано с нарушением функции филаггрина — белка, участвующего в агрегации кератиновых филаментов в верхних слоях эпидермиса и удержании липидов и белков между корнеоцитами. Зачастую нарушение функции филаггрина сопровождается присоединением вторичной инфекции и высоким риском развития других аллергических заболеваний. Происходит это по причине нарушения процесса терминальной дифференцировки клеток эпидермиса и, как следствие, целостности кожного барьера. В связи с этим основой терапии АтД является длительное регулярное использование эмолентов. Более эффективного лечения пациентов с АтД удалось добиться с внедрением в практику нового класса эмолентов («эмоленты плюс»), снижающих активность воспалительных процессов в коже за счет замещения структурных компонентов нарушенного эпидермального барьера.

Atopic dermatitis (AtD) is multifactorial inflammatory skin disease, one of the aspects of its pathogenesis is epidermal barrier dysfunction. Early development of AtD is associated with filaggrin dysfunction. Filaggrin is a protein involved in aggregation of keratin filaments in the upper layers of epidermis and the retention of lipids and proteins between corneocytes. Frequently, filaggrin dysfunction can be accompanied with secondary infection and high risk of other allergic diseases development. This can happen due to disturbance in terminal differentiation of epidermal cells and, as consequence, malfunction of epidermal barrier. Thus, the long regular use of emollients is the basis of AtD therapy. New class of emollients (“emollents plus”) allowed us to achieve more significant treatment results in patients with AtD. These emollients reduce inflammatory process activity in the skin by replacing structural components of abnormal epidermal barrier.

атопический дерматитфилаггринэмолентыфилагринолэпидермальный барьерроговой слойцерамидыatopic dermatitisfilaggrinemollientfilagrinolepidermal barriercorneal layerceramidesНе указан.Not specified.ReferencesMaliyar K, Sibbald C, Pope E, et al. Diagnosis and Management of Atopic Dermatitis. Adv Skin Wound Care. 2018;31(12):538-550. doi: 10.1097/01.asw.0000547414.38888.8dMaliyar K, Sibbald C, Pope E, et al. Diagnosis and Management of Atopic Dermatitis. Adv Skin Wound Care. 2018;31(12):538-550. doi: 10.1097/01.asw.0000547414.38888.8dDrucker AM, Wang AR, Li WQ, et al. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. J Investig Dermatol. 2017;137(1):26-30. doi: 10.1016/j.jid.2016.07.012Drucker AM, Wang AR, Li WQ, et al. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. J Investig Dermatol. 2017;137(1):26-30. doi: 10.1016/j.jid.2016.07.012Xu X, van Galen LS, Koh MJ., et al. Factors influencing quality of life in children with atopic dermatitis and their caregivers: A crosssectional study. Sci Rep. 2019;9(1):15990. doi: 10.1038/s41598-019-51129-5Xu X, van Galen LS, Koh MJ., et al. Factors influencing quality of life in children with atopic dermatitis and their caregivers: A crosssectional study. Sci Rep. 2019;9(1):15990. doi: 10.1038/s41598-019-51129-5Mallol J, Crane J, von Mutius E, et al. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesis. Allergol Immunopathol. 2013;41(2):73-85. doi: 10.1016/j.aller.2012.03.001Mallol J, Crane J, von Mutius E, et al. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesis. Allergol Immunopathol. 2013;41(2):73-85. doi: 10.1016/j.aller.2012.03.001Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-743. doi: 10.1016/s0140-6736(06)69283-0Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-743. doi: 10.1016/s0140-6736(06)69283-0Larsen FS, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am. 2002;22(1):1-24. doi: 10.1016/s0889-8561(03)00066-3Larsen FS, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am. 2002;22(1):1-24. doi: 10.1016/s0889-8561(03)00066-3National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES) body composition procedures manual. Centers for Disease Control and Prevention. Hyattsville, MD; 2006.National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES) body composition procedures manual. Centers for Disease Control and Prevention. Hyattsville, MD; 2006.Deckers I.A., McLean S., Linssen S., et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: A systematic review of epidemiologic studies. PLoS One. 2012;7(7):e39803. doi: 10.1371/journal.pone.0039803Deckers I.A., McLean S., Linssen S., et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: A systematic review of epidemiologic studies. PLoS One. 2012;7(7):e39803. doi: 10.1371/journal.pone.0039803Kowalska-Olędzka E, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126-128. doi: 10.1080/21556660.2019.1619570Kowalska-Olędzka E, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126-128. doi: 10.1080/21556660.2019.1619570Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131(1):67-73. doi: 10.1038/jid.2010.251Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131(1):67-73. doi: 10.1038/jid.2010.251Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8):2867. doi: 10.3390/ijms21082867Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8):2867. doi: 10.3390/ijms21082867Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest. 2012;122(2):440-447. doi: 10.1172/JCI57416Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest. 2012;122(2):440-447. doi: 10.1172/JCI57416Michael JC, Simon GD, Yiannis V, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8):1892-1908. doi: 10.1038/jid.2009.133Michael JC, Simon GD, Yiannis V, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8):1892-1908. doi: 10.1038/jid.2009.133Bosko CA. Skin Barrier Insights: From Bricks and Mortar to Molecules and Microbes. J Drugs Dermatol. 2019;18(1s):s63-s67.Bosko CA. Skin Barrier Insights: From Bricks and Mortar to Molecules and Microbes. J Drugs Dermatol. 2019;18(1s):s63-s67.Wickett RR, Visscher MO. Structure and function of the epidermal barrier. Am J Infect Control. 2006;34(10):S98-S110. doi: 10.1016/j.ajic.2006.05.295Wickett RR, Visscher MO. Structure and function of the epidermal barrier. Am J Infect Control. 2006;34(10):S98-S110. doi: 10.1016/j.ajic.2006.05.295Matsui T, Amagai M. Dissecting the formation, structure and barrier function of the stratum corneum. Int Immunol. 2015;27(6):269-280. doi: 10.1093/intimm/dxv013Matsui T, Amagai M. Dissecting the formation, structure and barrier function of the stratum corneum. Int Immunol. 2015;27(6):269-280. doi: 10.1093/intimm/dxv013Segre JA. Epidermal barrier formation and recovery in skin disorders. J Clin Invest. 2006;116(5):1150-1158. doi: 10.1172/JCI28521Segre JA. Epidermal barrier formation and recovery in skin disorders. J Clin Invest. 2006;116(5):1150-1158. doi: 10.1172/JCI28521Natsuga K. Epidermal barriers. Cold Spring Harb Perspect Med. 2014;4(4):a018218. doi: 10.1101/cshperspect.a018218Natsuga K. Epidermal barriers. Cold Spring Harb Perspect Med. 2014;4(4):a018218. doi: 10.1101/cshperspect.a018218Munoz-Garcia A, Thomas CP Keeney DS, et al. The importance of the lipoxygenase-hepoxilin pathway in the mammalian epidermal barrier. Biochim Biophys Acta. 2014;1841(3):401-408. doi: 10.1016/j.bbalip.2013.08.020Munoz-Garcia A, Thomas CP Keeney DS, et al. The importance of the lipoxygenase-hepoxilin pathway in the mammalian epidermal barrier. Biochim Biophys Acta. 2014;1841(3):401-408. doi: 10.1016/j.bbalip.2013.08.020Nakagawa N, Sakai S, Matsumoto M, et al. Relationship between NMF (lactate and potassium) content and the physical properties of the stratum corneum in healthy subjects. J Invest Dermatol. 2004;122(3):755-763. doi: 10.1111/j.0022-202X.2004.22317.xNakagawa N, Sakai S, Matsumoto M, et al. Relationship between NMF (lactate and potassium) content and the physical properties of the stratum corneum in healthy subjects. J Invest Dermatol. 2004;122(3):755-763. doi: 10.1111/j.0022-202X.2004.22317.xSroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci. 2021;22(8):4130. doi: 10.3390/ijms22084130Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci. 2021;22(8):4130. doi: 10.3390/ijms22084130Presland RB, Haydock PV, Fleckman P, et al. Characterization of the human epidermal profilaggrin gene. Genomic organization and identification of an S-100-like calcium binding domain at the amino terminus. J Biol Chem. 1992;267:23772-23781.Presland RB, Haydock PV, Fleckman P, et al. Characterization of the human epidermal profilaggrin gene. Genomic organization and identification of an S-100-like calcium binding domain at the amino terminus. J Biol Chem. 1992;267:23772-23781.Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446. doi: 10.1038/ng1767Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446. doi: 10.1038/ng1767Brown SJ, Irvine AD. Atopic eczema and the filaggrin story. Semin Cutan Med Surg. 2008;27(2):128-137. doi: 10.1016/j.sder.2008.04.001Brown SJ, Irvine AD. Atopic eczema and the filaggrin story. Semin Cutan Med Surg. 2008;27(2):128-137. doi: 10.1016/j.sder.2008.04.001Izadi N, Luu M, Ong PY, Tam JS. The Role of Skin Barrier in the Pathogenesis of Food Allergy. Children (Basel). 2015;2(3):382-402. doi: 10.3390/children2030382Izadi N, Luu M, Ong PY, Tam JS. The Role of Skin Barrier in the Pathogenesis of Food Allergy. Children (Basel). 2015;2(3):382-402. doi: 10.3390/children2030382Osawa R, Akiyama M, Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int. 2011;60(1):1-9. doi: 10.2332/allergolint.10-RAI-0270Osawa R, Akiyama M, Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int. 2011;60(1):1-9. doi: 10.2332/allergolint.10-RAI-0270Brown SJ, McLean WH. Eczema genetics: current state of knowledge and future goals. J Invest Dermatol. 2009;129(3):543-552. doi: 10.1038/jid.2008.413Brown SJ, McLean WH. Eczema genetics: current state of knowledge and future goals. J Invest Dermatol. 2009;129(3):543-552. doi: 10.1038/jid.2008.413O'Regan GM, Sandilands A, McLean WHI, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2008;122(4):689-693. doi: 10.1016/j.jaci.2008.08.002O'Regan GM, Sandilands A, McLean WHI, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2008;122(4):689-693. doi: 10.1016/j.jaci.2008.08.002Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315-1327. doi: 10.1056/NEJMra1011040Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315-1327. doi: 10.1056/NEJMra1011040McPherson T. Current Understanding in Pathogenesis of Atopic Dermatitis. Indian J Dermatol. 2016;61(6):649-655. doi: 10.4103/0019-5154.193674McPherson T. Current Understanding in Pathogenesis of Atopic Dermatitis. Indian J Dermatol. 2016;61(6):649-655. doi: 10.4103/0019-5154.193674McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280-291. doi: 10.1016/j.jaci.2012.12.668McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280-291. doi: 10.1016/j.jaci.2012.12.668Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011;3(2):6773. doi: 10.4168/aair.2011.3.2.67Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011;3(2):6773. doi: 10.4168/aair.2011.3.2.67Belgrave DC, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014;11(10):e1001748. doi: 10.1371/journal.pmed.1001748Belgrave DC, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014;11(10):e1001748. doi: 10.1371/journal.pmed.1001748Irvine A.D., Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide. Br J Dermatol. 2019;181(5):895-906. doi: 10.1111/bjd.17766Irvine A.D., Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide. Br J Dermatol. 2019;181(5):895-906. doi: 10.1111/bjd.17766Chan A, Terry W, Zhang H, et al. Filaggrin mutations increase allergic airway disease in childhood and adolescence through interactions with eczema and aeroallergen sensitization. Clin Exp Allergy. 2018;48(2):147-155. doi: 10.1111/cea.13077Chan A, Terry W, Zhang H, et al. Filaggrin mutations increase allergic airway disease in childhood and adolescence through interactions with eczema and aeroallergen sensitization. Clin Exp Allergy. 2018;48(2):147-155. doi: 10.1111/cea.13077Venkataraman D, Soto-Ramfrez N, Kurukulaaratchy RJ, et al. Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence. J Allergy Clin Immunol. 2014;134(4):876-882.e4. doi: 10.1016/j.jaci.2014.07.033Venkataraman D, Soto-Ramfrez N, Kurukulaaratchy RJ, et al. Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence. J Allergy Clin Immunol. 2014;134(4):876-882.e4. doi: 10.1016/j.jaci.2014.07.033Rodnguez E, Baurecht H, Herberich E, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J Allergy Clin Immunol. 2009;123(6):1361-1370. e7. doi: 10.1016/j.jaci.2009.03.036Rodnguez E, Baurecht H, Herberich E, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J Allergy Clin Immunol. 2009;123(6):1361-1370. e7. doi: 10.1016/j.jaci.2009.03.036Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filag-grin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol. 2010;126(6):1184-1190. doi: 10.1016/j.jaci.2010.09.015Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol. 2010;126(6):1184-1190. doi: 10.1016/j.jaci.2010.09.015Rabinowitz LG, Esterly NB. Atopic dermatitis and ichthyosis vulgaris. Pediatr Rev. 1994;15(6):220-226; quiz 226. doi: 10.1542/pir.15-6-220Rabinowitz LG, Esterly NB. Atopic dermatitis and ichthyosis vulgaris. Pediatr Rev. 1994;15(6):220-226; quiz 226. doi: 10.1542/pir.15-6-220Sehgal VN, Khurana A, Mendiratta V, et al. Atopic dermatitis: Clinical connotations, especially a focus on concomitant atopic undertones in immunocompromised/susceptible genetic and metabolic disorders. Indian J Dermatol. 2016;(61):241-250. doi: 10.4103/0019-5154.182433Sehgal VN, Khurana A, Mendiratta V, et al. Atopic dermatitis: Clinical connotations, especially a focus on concomitant atopic undertones in immunocompromised/susceptible genetic and metabolic disorders. Indian J Dermatol. 2016;(61):241-250. doi: 10.4103/0019-5154.182433Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150-155. doi: 10.1016/j.jaci.2007.04.031Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150-155. doi: 10.1016/j.jaci.2007.04.031Arakawa H, Shimojo N, Katoh N, et al. Consensus statements on pediatric atopic dermatitis from dermatology and pediatrics practitioners in Japan: Goals of treatment and topical therapy. Allergol Int. 2020;69(1):84-90. doi: 10.1016/j.alit.2019.08.006Arakawa H, Shimojo N, Katoh N, et al. Consensus statements on pediatric atopic dermatitis from dermatology and pediatrics practitioners in Japan: Goals of treatment and topical therapy. Allergol Int. 2020;69(1):84-90. doi: 10.1016/j.alit.2019.08.006Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.Reda AM, Ayman E, Ebraheem AI, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East empha-sizing the importance of sensitive skin areas. J Dermatolog Treat. 2019;30(4):366-373. doi: 10.1080/09546634.2018.1524823Reda AM, Ayman E, Ebraheem AI, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East empha-sizing the importance of sensitive skin areas. J Dermatolog Treat. 2019;30(4):366-373. doi: 10.1080/09546634.2018.1524823Catherine M., Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract. 2012;2012:836931. doi: 10.1155/2012/836931Catherine M., Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract. 2012;2012:836931. doi: 10.1155/2012/836931Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi: 10.1016/j.jaad.2014.03.023Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi: 10.1016/j.jaad.2014.03.023Hebert AA, Rippke, F, Weber TM, et al. Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence. Am J Clin Dermatol. 2020;21(5):641-655. doi: 10.1007/s40257-020-00529-9Hebert AA, Rippke, F, Weber TM, et al. Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence. Am J Clin Dermatol. 2020;21(5):641-655. doi: 10.1007/s40257-020-00529-9Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. doi: 10.1016/j.jaad.2009.11.011Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. doi: 10.1016/j.jaad.2009.11.011Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-823. doi: 10.1016/j.jaci.2014.08.005Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-823. doi: 10.1016/j.jaci.2014.08.005Lowe A, Su J, Tang M, et al. PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy. BMJ Open. 2019;9(3):e024594. doi: 10.1136/bmjopen-2018-024594Lowe A, Su J, Tang M, et al. PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy. BMJ Open. 2019;9(3):e024594. doi: 10.1136/bmjopen-2018-024594L0drup Carlsen KC, Rehbinder EM, Skjerven HO, et al. Preventing atopic dermatitis and ALLergies in children — the PreventADALL study. Allergy. 2018; 73(10):2063-2070. doi: 10.1111/all.13468L0drup Carlsen KC, Rehbinder EM, Skjerven HO, et al. Preventing atopic dermatitis and ALLergies in children — the PreventADALL study. Allergy. 2018; 73(10):2063-2070. doi: 10.1111/all.13468Purnamawati S, Indrastuti N, Danarti R, Saefudin T. The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review. Clin Med Res. 2017;15(3-4):75-87. doi: 10.3121/cmr.2017.1363Purnamawati S, Indrastuti N, Danarti R, Saefudin T. The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review. Clin Med Res. 2017;15(3-4):75-87. doi: 10.3121/cmr.2017.1363Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61-67. doi: 10.1159/000096915Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61-67. doi: 10.1159/000096915Hon KL, Pong NH, Wang SS, et al. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients. Drugs R D. 2013;13(1):37-42. doi: 10.1007/s40268-013-0004-xHon KL, Pong NH, Wang SS, et al. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients. Drugs R D. 2013;13(1):37-42. doi: 10.1007/s40268-013-0004-xWollenberg A, Folster-Holst R, Saint Aroman M, et al. Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2018;32 (Suppl 1):1-15. doi: 10.1111/jdv.14846Wollenberg A, Folster-Holst R, Saint Aroman M, et al. Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2018;32 (Suppl 1):1-15. doi: 10.1111/jdv.14846Topical skin care compositions. Patent. Publication Number: WO 2018/198039 A1. Publication Date: 01.11.2018. International Application No: PCT/IB2018/052866. International Filing Date: 25.04.2018. Applicant: DR. REDDY'S LABORATORIES LIMITED.Topical skin care compositions. Patent. Publication Number: WO 2018/198039 A1. Publication Date: 01.11.2018. International Application No: PCT/IB2018/052866. International Filing Date: 25.04.2018. Applicant: DR. REDDY'S LABORATORIES LIMITED.Mohammed D, Crowther JM, Matts PJ, et al. Influence of niacinamide containing formulations on the molecular and biophysical properties of the stratum corneum. Int J Pharm. 2013;441(1-2):192-201. doi: 10.1016/j.ijpharm.2012.11.043Mohammed D, Crowther JM, Matts PJ, et al. Influence of niacinamide containing formulations on the molecular and biophysical properties of the stratum corneum. Int J Pharm. 2013;441(1-2):192-201. doi: 10.1016/j.ijpharm.2012.11.043Coderch L, Lopez O, de la Maza A, Parra JL. Ceramides and skin function. Am J Clin Dermatol. 2003;4(2):107-129. doi: 10.2165/00128071-200304020-00004Coderch L, Lopez O, de la Maza A, Parra JL. Ceramides and skin function. Am J Clin Dermatol. 2003;4(2):107-129. doi: 10.2165/00128071-200304020-00004Kim ME, Kim HK, Kim DH, et al. Glycyrrhetinic acid from licorice root impairs dendritic cells maturation and Th1 immune responses. Immunopharmacol Immunotoxicol. 2013;35(3):329-335. doi: 10.3109/08923973.2013.768636Kim ME, Kim HK, Kim DH, et al. Glycyrrhetinic acid from licorice root impairs dendritic cells maturation and Th1 immune responses. Immunopharmacol Immunotoxicol. 2013;35(3):329-335. doi: 10.3109/08923973.2013.768636Akihisa T, Kojima N, Kikuchi T, et al. Anti- inflammatory and chemopreventive effects of triterpene cinnamates and acetates from shea fat. J Oleo Sci. 2010;59(6):273-280. doi: 10.5650/jos.59.273Akihisa T, Kojima N, Kikuchi T, et al. Anti-inflammatory and chemopreventive effects of triterpene cinnamates and acetates from shea fat. J Oleo Sci. 2010;59(6):273-280. doi: 10.5650/jos.59.273Scapagnini G, Davinelli S, Di Renzo L, et al. Cocoa bioactive compounds: significance and potential for the maintenance of skin health. Nutrients. 2014;6(8):3202-3213. doi: 10.3390/nu6083202Scapagnini G, Davinelli S, Di Renzo L, et al. Cocoa bioactive compounds: significance and potential for the maintenance of skin health. Nutrients. 2014;6(8):3202-3213. doi: 10.3390/nu6083202Abril-Gil M, Massot-Cladera M, Perez-Cano FJ, et al. A diet enriched with cocoa prevents IgE synthesis in a rat allergy model. Pharmacol Res. 2012;65(6):603-608. doi: 10.1016/j.phrs.2012.02.001Abril-Gil M, Massot-Cladera M, Perez-Cano FJ, et al. A diet enriched with cocoa prevents IgE synthesis in a rat allergy model. Pharmacol Res. 2012;65(6):603-608. doi: 10.1016/j.phrs.2012.02.001Mandawgade SD, Patravale VB. Formulation and evaluation of exotic fat based cosmeceuticals for skin repair. Indian J Pharm Sci. 2008;70(4):539-542. doi: 10.4103/0250-474X.44615Mandawgade SD, Patravale VB. Formulation and evaluation of exotic fat based cosmeceuticals for skin repair. Indian J Pharm Sci. 2008;70(4):539-542. doi: 10.4103/0250-474X.44615

The authors declare that there are no conflicts of interest present.